Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD.

Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.

PMID:
30442502
2.

Organochlorine Levels in Plasma and Risk of Multiple Myeloma.

Weber L, Song K, Boyle T, Gaudreau É, Lai A, Sutherland HJ, LeBlanc A, Spinelli JJ.

J Occup Environ Med. 2018 Oct;60(10):911-916. doi: 10.1097/JOM.0000000000001387.

PMID:
30289833
3.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

4.

Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.

Limvorapitak W, Barnett MJ, Hogge DE, Forrest DL, Nevill TJ, Narayanan S, Power MM, Nantel SH, Broady R, Song KW, Toze CL, Mourad YA, Sutherland HJ, Gerrie AS, White J, Sanford DS.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e481-e491. doi: 10.1016/j.clml.2018.07.290. Epub 2018 Jul 17.

PMID:
30100330
5.

Organochlorine Levels in Plasma and Risk of Multiple Myeloma: Organochlorines and risk of multiple myeloma.

Weber L, Song K, Boyle T, Gaudreau É, Lai A, Sutherland HJ, Leblanc A, Spinelli JJ.

J Occup Environ Med. 2018 Jun 21. doi: 10.1097/JOM.0000000000001387. [Epub ahead of print]

PMID:
29933318
6.

Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.

Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K, Slack GW, Abou Mourad Y, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Sanford DS, Sutherland HJ, Tucker T, Toze CL, Sehn LH, Broady R, Gerrie AS.

Br J Haematol. 2018 Jun;181(6):782-790. doi: 10.1111/bjh.15262. Epub 2018 May 9.

PMID:
29741758
7.

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF.

Cancer. 2016 Jul 1;122(13):2050-6. doi: 10.1002/cncr.30026. Epub 2016 May 18.

8.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM.

Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

PMID:
26778538
9.

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.

Nair AP, Barnett MJ, Broady RC, Hogge DE, Song KW, Toze CL, Nantel SH, Power MM, Sutherland HJ, Nevill TJ, Abou Mourad Y, Narayanan S, Gerrie AS, Forrest DL.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1437-44. doi: 10.1016/j.bbmt.2015.04.005. Epub 2015 Apr 10.

10.

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.

Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):341-8. doi: 10.1016/j.clml.2014.12.015. Epub 2015 Jan 3.

PMID:
25656914
11.

Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.

Toze CL, Dalal CB, Nevill TJ, Gillan TL, Abou Mourad YR, Barnett MJ, Broady RC, Forrest DL, Hogge DE, Nantel SH, Power MM, Song KW, Sutherland HJ, Smith CA, Narayanan S, Young SS, Connors JM, Shepherd JD.

Br J Haematol. 2012 Jul;158(2):174-185. doi: 10.1111/j.1365-2141.2012.09170.x. Epub 2012 May 29.

PMID:
22640008
12.

Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.

Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL.

Leuk Lymphoma. 2012 Jul;53(7):1321-6. doi: 10.3109/10428194.2011.652108. Epub 2012 Mar 5.

PMID:
22192245
13.

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Lantz KC, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):44-9. doi: 10.3816/CLML.2011.n.005.

PMID:
21454189
14.

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).

Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, Smith CA, Song KW.

Leuk Lymphoma. 2011 Jan;52(1):34-41. doi: 10.3109/10428194.2010.531409. Epub 2010 Dec 6.

PMID:
21133716
15.

Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.

Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL.

Biol Blood Marrow Transplant. 2010 May;16(5):639-46. doi: 10.1016/j.bbmt.2009.11.026. Epub 2010 Feb 4.

16.

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.

Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC.

Bone Marrow Transplant. 2010 Feb;45(2):295-302. doi: 10.1038/bmt.2009.128. Epub 2009 Jul 13.

PMID:
19597425
17.

IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA.

Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015.

18.

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.

Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators.

Clin Lymphoma Myeloma. 2008 Dec;8(6):352-5. doi: 10.3816/CLM.2008.n.051.

PMID:
19064400
19.

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.

Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA.

Leuk Res. 2009 Feb;33(2):271-5. doi: 10.1016/j.leukres.2008.07.015. Epub 2008 Aug 31.

PMID:
18762338
20.

Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results.

Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, Voss NJ, Brinkman RR, Smith CA, Toze CL.

Bone Marrow Transplant. 2008 Nov;42(9):601-8. doi: 10.1038/bmt.2008.220. Epub 2008 Aug 11.

PMID:
18695664
21.

Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.

Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA.

Bone Marrow Transplant. 2008 Nov;42(10):659-66. doi: 10.1038/bmt.2008.226. Epub 2008 Aug 4.

PMID:
18679372
22.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL.

J Clin Oncol. 2007 Sep 1;25(25):3892-901. Epub 2007 Aug 6.

PMID:
17679727
23.

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.

Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. Epub 2007 May 29.

24.
25.

Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.

Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC.

Ann Oncol. 2007 Jul;18(7):1246-52. Epub 2007 Apr 17.

PMID:
17442662
26.

Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.

Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM.

Ann Oncol. 2007 Mar;18(3):535-40. Epub 2006 Dec 8.

PMID:
17158775
27.

Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.

Lin Y, Bruyère H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL.

Cancer Genet Cytogenet. 2006 Oct 1;170(1):16-23.

PMID:
16965950
28.

Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.

Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, Forrest DL, Horsman DE, Smith C, Song K, Sutherland HJ, Toze CL, Nevill TJ, Nantel SH, Hogge DE.

Leuk Lymphoma. 2006 Jul;47(7):1245-52.

PMID:
16923553
29.

Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.

Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM.

Br J Haematol. 2006 Jun;133(6):634-7.

PMID:
16704438
30.

Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.

Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ.

Biol Blood Marrow Transplant. 2006 Apr;12(4):480-9.

31.

Shifting to outpatient management of acute myeloid leukemia: a prospective experience.

Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC.

Ann Oncol. 2006 May;17(5):763-8. Epub 2006 Feb 23.

PMID:
16497826
32.

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.

Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM.

J Clin Oncol. 2005 Nov 1;23(31):7994-8002. Epub 2005 Oct 3.

PMID:
16204014
33.

Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.

Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW.

Br J Haematol. 2005 Oct;131(2):223-30.

PMID:
16197454
34.

Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease.

Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, Song KW, Smith CA, Lipton J.

Bone Marrow Transplant. 2005 Nov;36(9):825-30.

PMID:
16151430
35.

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.

Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M, Keating A.

Leuk Lymphoma. 2005 Apr;46(4):525-31.

PMID:
16019480
36.

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ.

Blood. 2005 Aug 15;106(4):1473-8. Epub 2005 May 3.

PMID:
15870180
37.

Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation.

Toze CL, Barnett MJ, Connors JM, Gascoyne RD, Voss NJ, Nantel SH, Nevill TJ, Shepherd JD, Sutherland HJ, Lavoie JC, Forrest DL, Song KW, Hogge DE.

Br J Haematol. 2004 Nov;127(3):311-21.

PMID:
15491292
38.

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation.

Kuruvilla J, Forrest DL, Lavoie JC, Nantel SH, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ.

Bone Marrow Transplant. 2004 Dec;34(11):969-73.

PMID:
15489882
40.

Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21).

Khoury H, Dalal BI, Nantel SH, Horsman DE, Lavoie JC, Shepherd JD, Hogge DE, Toze CL, Song KW, Forrest DL, Sutherland HJ, Nevill TJ.

Mod Pathol. 2004 Oct;17(10):1211-6.

41.

Acute myelogenous leukemia with t(8;21)--identification of a specific immunophenotype.

Khoury H, Dalal BI, Nevill TJ, Horsman DE, Barnett MJ, Shepherd JD, Toze CL, Conneally EA, Sutherland HJ, Hogge DE, Nantel SH.

Leuk Lymphoma. 2003 Oct;44(10):1713-8.

PMID:
14692523
42.

Telomerase is limiting the growth of acute myeloid leukemia cells.

Röth A, Vercauteren S, Sutherland HJ, Lansdorp PM.

Leukemia. 2003 Dec;17(12):2410-7.

PMID:
14562114
43.

Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.

Forrest DL, Nevill TJ, Naiman SC, Le A, Brockington DA, Barnett MJ, Lavoie JC, Nantel SH, Song KW, Shepherd JD, Sutherland HJ, Toze CL, Davis JH, Hogge DE.

Bone Marrow Transplant. 2003 Nov;32(9):915-23.

PMID:
14561993
44.

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.

Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ, Tsang P, Hogge DE.

Blood. 2004 Jan 1;103(1):333-9. Epub 2003 Sep 4.

PMID:
12958065
45.

Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).

Seftel MD, Bruyere H, Copland M, Hogge DE, Horsman DE, Nantel SH, Shepherd JD, Lavoie JC, Le A, Sutherland HJ, Toze CL, Nevill TJ.

Eur J Haematol. 2002 Oct;69(4):193-9.

PMID:
12431237
46.

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE.

Biol Blood Marrow Transplant. 2002;8(8):435-43.

47.

A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood.

Louis SA, Zapf R, Clarke E, Thomas TE, Sutherland HJ.

Cytotherapy. 2001;3(6):489-504.

PMID:
11953033
48.

CD133 (AC133) expression on AML cells and progenitors.

Vercauteren SM, Sutherland HJ.

Cytotherapy. 2001;3(6):449-59.

PMID:
11953029
49.

Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies.

Knight JA, Sutherland HJ, Glendon G, Boyd NF, Andrulis IL; Ontario Cancer Genetics Network.

Ann Epidemiol. 2002 Jan;12(1):27-33.

PMID:
11750237
50.

The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario.

Sutherland HJ, Lacroix J, Knight J, Andrulis IL, Boyd NF; Ontario Cancer Genetics Network.

J Clin Epidemiol. 2001 Jan;54(1):93-8.

PMID:
11165472

Supplemental Content

Loading ...
Support Center